HZNP - ホライゾン・ファ―マ (Horizon Pharma plc) ホライゾン・ファ―マ

 HZNPのチャート


 HZNPの企業情報

symbol HZNP
会社名 Horizon Pharma Plc (ホライゾン・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ホライゾン・ファーマ(Horizon Pharma Public Limited Company)はバイオ医薬品会社である。同社は満たされていない医療ニーズに対処する差別化された接近可能な医薬品の特定・開発・取得・商業化に従事する。同社は希少疾病、リウマチ、プライマリケア事業セグメントを通じて11の医薬品を販売する。同社が販売する医薬品は、ACTIMMUNE(インターフェロンγ-1b)、BUPHENYL(フェニル酪酸ナトリウム)錠剤および粉末、DUEXIS(イブプロフェン/ファモチジン)、KRYSTEXXA(ペグロチナーゼ)、MIGERGOT(エルゴタミン酒石酸塩およびカフェイン坐剤)、2重量%のPENNSAID(ジクロフェナクナトリウム局所溶液)、またはPENNSAID 2%、PROCYSBI(酒石酸水素システアミン)遅延放出カプセル、QUINSAIR(エアロゾル化形態のレボフロキサシン)、RAVICTI(グリセロールフェニルブチラート)経口液体、RAYOS (プレドニゾン)遅延放出錠剤およびVIMOVO(ナプロキセン/エソメプラゾールマグネシウム)を含む。   ホライゾン・ファ―マはアイルランドのバイオ医薬品持株会社。関節炎、疼痛、炎症性疾患向けの医薬品を開発、販売する。主要製品はイブプロフェンとファモチジンを組み合わせた単一錠剤のDUEXIS、成人向けの関節リウマチ治療薬RAYOS/LODOTRA(米国内でRAYOS、米国外ではLODOTRAとして提供)、およびVIMOVOなど。   Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
本社所在地 Connaught House 1st Floor 1 Burlington Road Dublin 4 D04 C5Y6 IRL
代表者氏名 Timothy P. Walbert ティモシー・P・ウォルバーツ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +353 1-772-2100
設立年月日 38504
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 1010人
url www.horizonpharma.com
nasdaq_url https://www.nasdaq.com/symbol/hznp
adr_tso
EBITDA EBITDA(百万ドル) 89.14000
終値(lastsale) 18.16
時価総額(marketcap) 3025996042.08
時価総額 時価総額(百万ドル) 3177.629
売上高 売上高(百万ドル) 172.581
企業価値(EV) 企業価値(EV)(百万ドル) 4352.536
当期純利益 当期純利益(百万ドル) -375.58200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Horizon Pharma PLC revenues increased 3% to $526.7M. Net loss decreased 37% to $190.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development - Balancing val decrease of 78% to $37.3M (expense) Interest Expense - Net decrease of 3% to $61.5M (expense).

 HZNPのテクニカル分析


 HZNPのニュース

   Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares  2020/08/11 21:00:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 13,570,000 of its ordinary shares at a price to the public of $71.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,770,000 additional ordinary shares. The net proceeds to the Company from this offering are expected to be approximately $919.3 million, after deducting underwriting discounts and other estimated o
   Bullish Signal Could Catapult Pharma Stock Higher  2020/08/10 18:57:12 Schaeffers Investment Research
Horizon Therapeutics stock is flashing a bull signal that could catapult it to a new record high
   Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crain’s Chicago Business  2020/08/10 13:00:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the Crain’s Chicago Business 2020 Best Places to Work in Chicago list. “It’s a tremendous honor that Crain’s Chicago Business ranked us among the Best Places to Work in Chicago where many Horizon employees live and work,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Despite these challenging times, working at Horizon remains grounded in the strength of our c
   Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares  2020/08/07 03:20:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 11,800,000 of its ordinary shares at a price to the public of $71.00 per share. The net proceeds to the Company from this offering are expected to be approximately $798.9 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company. The Company has also granted the underwriters a 30-day option to purchase up to an add
   Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune  2020/08/06 13:00:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the 2020 Fortune Best Workplaces for Millennials™ list. Horizon ranked 7th among 25 companies in the small and medium company category in its first year on the list. “We’re proud that Fortune and Great Place to Work recognized the focus we put on developing employees at each phase of their careers, including those in the beginning stages,” said Tim Walbert, chairman, president and chief ex
   Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares  2020/08/07 03:20:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 11,800,000 of its ordinary shares at a price to the public of $71.00 per share. The net proceeds to the Company from this offering are expected to be approximately $798.9 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company. The Company has also granted the underwriters a 30-day option to purchase up to an add
   Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune  2020/08/06 13:00:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the 2020 Fortune Best Workplaces for Millennials™ list. Horizon ranked 7th among 25 companies in the small and medium company category in its first year on the list. “We’re proud that Fortune and Great Place to Work recognized the focus we put on developing employees at each phase of their careers, including those in the beginning stages,” said Tim Walbert, chairman, president and chief ex
   Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares  2020/08/05 20:01:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is offering to sell $700,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $105,000,000 of ordinary shares in the public offering. Citigroup, Morgan Stanley, J.P. Morgan, Piper Sandler and Stifel are acting as joint book-running managers for the offering. Cowen is acting as a financial advisor
   Thinking about buying stock in Sorrento Therapeutics, Aerpio Pharmaceuticals, Horizon Therapeutics, Riot Blockchain, or Royal Caribbean Cruises?  2020/08/05 13:38:00 PR Newswire
NEW YORK, Aug. 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, ARPO, HZNP, RIOT, and RCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Recap: Horizon Therapeutics Q2 Earnings  2020/08/05 07:46:00 Benzinga
Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 18.37% over the …
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   Target Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for People Living with Uncontrolled Gout  2020/07/22 12:00:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company has reached target patient enrollment for its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA [(MIRROR) randomized controlled trial (RCT)]. MIRROR RCT is the largest randomized trial to evaluate the efficacy and safety of the concomitant use of KRYSTEXXA® (pegloticase injection) with methotrexate as an immunomodulator to help more people with chronic g
   The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat  2020/07/22 11:24:35 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer COVID-19 diagnostics testing to the NFL) ResMed Inc. (NYSE: RMD ) Retrophin Inc (NASDAQ: RTRX ) Trevena Inc (NASDAQ: TRVN ) Twist Bioscience Corp (NASDAQ: TWST ) Veracyte Inc (NASDAQ: VCYT ) West Pharmaceutical Services Inc.
   Why Is Horizon Therapeutics (HZNP) Up 13.2% Since Last Earnings Report?  2020/06/05 15:31:51 Zacks Investment Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?  2020/04/29 16:34:02 Zacks Investment Research
Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (医薬品 米国株 ホライゾン・ファ―マ HZNP Horizon Pharma plc)

 twitter  (公式ツイッターやCEOツイッターなど)